StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Noxafil (posaconazole, legacy) by Quarter

Noxafil (posaconazole, legacy) — International reported growth YoY (%) (%)

QuarterlyAnnual

Merck Noxafil (posaconazole, legacy): -12.0% in Q4 2024, down 5.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2024
-12.0%
Period ended Dec 31, 2024
Change on a year earlier
-5.0 pts
-7.0% in Q4 2023
History
22 quarters
Since Q4 2017
Sources
22
Documents cited below

Where the Q4 2024 figure comes from

“|| Noxafil | 36 | 46 | -23 | -2 | 4 | -149 | 37 | 43 | -12”

Source: Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗

Reported in Form 8-K Table 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNoxafil (posaconazole, legacy) — International reported growth YoY (%) (%)Year on yearSource
Q4 2024Dec 31, 2024-12.0%-5.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024-15.0%-12.0 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q1 2024Mar 31, 20244.0%–Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 2023-7.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 2023-3.0%-11.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q3 2022Sep 30, 20228.0%+39.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 2022-14.0%–Form 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 2022-9.0%+31.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 2021-25.0%–Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 2021-31.0%+3.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
Q1 2021Mar 31, 2021-40.0%-28.0 ptsForm 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q3 2020Sep 30, 2020-34.0%–Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 2020-27.0%-19.0 ptsForm 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 2020-12.0%-17.0 ptsForm 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2019Dec 31, 2019-7.0%-13.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q2 2019Jun 30, 2019-8.0%-37.0 ptsForm 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗

Cite this data

StockData. (2026). Merck Noxafil (posaconazole, legacy) (%), quarterly Q4 2017–Q4 2024 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-noxafil-intl-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.